Clinical Update: NRTX-1001 GABAergic Interneuron Cell Therapy for Drug-Resistant Focal Epilepsy
Year: 2026
Type: article
Abstract: Neurona Therapeutics is investigating NRTX-1001 cell therapy in two open-label, multicenter Phase 1/2 trials for drug-resistant unilateral (NCT05135091) and bilateral (NCT06422923) mesial temporal lobe epilepsy (MTLE). GABAergic cortical interneurons from the medial ganglionic eminence (MGE) are promising therapeutic targets in developing novel therapeutics for drug-resistant epilepsy. We developed a cortical MGE-type GABAergic interneuron cell therapy candidate, NRTX-1001, derived from human pluripotent stem cells for single-dose intra- hippocampal administration.
Source: Neurotherapeutics
Authors: John Hixson, Jerry Shih, Sharona Ben-Haim, Robert Beach, Harish Babu, David Spencer, Kim Burchiel, Rebecca O'Dwyer, Sepehr Sani, Derek Southwell, Matthew Luedke, Gautam Banik, Marina Bershteyn, Alessandro Bulfone, Brianna Feld, Luis Fuentealba, Stephanie Hughes, Ji-Hye Jung, Tia Kowal, Sonja Kriks, Rose Larios, Ngoc Minh Le, Seonok Lee, Sheri Madrid, Yves Maury, Catherine Priest, Cory Nicholas
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7212051997